Latest LEO Pharma News & Updates

See the latest news and media coverage for LEO Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
LEO Pharma

Medical dermatology pharmaceutical company

leo-pharma.com
Headquarters
Ballerup, Denmark
Founded year
1908
Company type
Private company
Number of employees
1,000–5,500

Last updated

Latest news about LEO Pharma

In short: LEO Pharma achieved robust 9% revenue growth in Q1 2026, expanded its dermatology portfolio, and progressed toward a Copenhagen IPO.

Company announcements

  • LEO Pharma

    LEO Pharma launches LOQTORZI in Denmark

    LOQTORZI is combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer. Clinical data show improved survival.

  • LEO Pharma

    LEO Pharma reports Q1 2026 revenue growth

    It achieves 9% CER growth, improved profitability, and acquired Replay, while advancing Anzupgo® and gaining Enstilar® approval in China.

  • LEO Pharma

    LEO Pharma acquires Replay.

    This acquisition deepens commitment to rare dermatology and expands innovation. It highlights collaboration with DEBRA Research.

  • LEO Pharma

    LEO Pharma acquires Replay

    The acquisition adds Replay's HSV gene therapy platform targeting rare skin diseases like DEB to LEO Pharma's pipeline. It combines dermatology expertise with next-generation therapy.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about LEO Pharma

Track LEO Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.